192 related articles for article (PubMed ID: 22350110)
1. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
Catalano A; Morabito N; Atteritano M; Basile G; Cucinotta D; Lasco A
Calcif Tissue Int; 2012 Apr; 90(4):279-85. PubMed ID: 22350110
[TBL] [Abstract][Full Text] [Related]
2. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
3. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
[TBL] [Abstract][Full Text] [Related]
5. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
[TBL] [Abstract][Full Text] [Related]
6. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
7. Characterization of and risk factors for the acute-phase response after zoledronic acid.
Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
[TBL] [Abstract][Full Text] [Related]
8. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
12. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
[TBL] [Abstract][Full Text] [Related]
13. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
Makras P; Anastasilakis AD; Polyzos SA; Bisbinas I; Sakellariou GT; Papapoulos SE
Calcif Tissue Int; 2011 May; 88(5):402-8. PubMed ID: 21305270
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
Kassi G; Papamichael K; Papaioannou G; Giagourta I; Thanou S; Triantaphyllopoulou M; Zapanti E; Papandroulaki F; Ktena V; Karga H
Immunol Invest; 2014; 43(6):544-55. PubMed ID: 24661204
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
17. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
18. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract][Full Text] [Related]
19. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]